The relevance of transforming growth factor β1 in pulmonary injury after radiation therapy

Lung Cancer

Volumn 19, Issue 2, 1998, Pages 109-120

  Anscher, Mitchell S ^a   Kong, Feng Ming ^a   Jirtle, Randy L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Lung cancer; Radiation therapy; Transforming growth factor

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG CANCER; LUNG INJURY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; TISSUE INJURY; WOUND HEALING;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031926223     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00076-7     Document Type: Article

References (89)

1. Ansari R., Tokars R., Fisher W., Pennington K., Mantravadi R., O'Connor T., Rynard S., Miller M., Einhorn L. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. Proc Am Soc Clin Oncol. 10:1991;241.
2. Anscher M.S., Crocker I.R., Jirtle R.L. Transforming growth factor β-1 expression in irradiated liver. Radiat Res. 122:1990;77-85.
3. Anscher M.S., Jirtle R.L. Role of transforming growth factor β and hepatocyte growth factor in late normal tissue effects of radiation. Radiat Oncol Invest. 1:1994;305-313.
4. Anscher M.S., Kong F.-M., Marks L.B., Bentel G.C., Jirtle R.L. Changes in plasma transforming growth factor beta and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys. 37:1997;253-258.
5. Anscher M.S., Kong F.-M., Murase T., Jirtle R.L. Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ Br J Radiol. 68:1995;331-333.
6. Anscher MS, Kong FM, Sporn T, Jirtle RL. Loss of a functioning mannose 6-phosphate/insulin-like growth factor 2 receptor may lead to an elevated plasma transforming growth factor β1 level: clinical implications. Proceedings of the 9th Lorne Cancer Conference, Abstract 101, 1997.
7. Anscher M.S., Murase T., Prescott D.M., Marks L.B., Reisenbichler H., Bentel G.C., Spencer D., Sherouse G., Jirtle R.L. Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys. 30:1994;671-676.
8. Anscher M.S., Peters W.P., Reisenbichler H., Petros W.P., Jirtle R.L. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl J Med. 328:1993;1592-1598.
9. Arriagada R., LeChevalier T., Quoix E., Ruffie P., DeCremoux H., Douillard J.Y., Taraye M., Pignon J.P., Laplanche A. Effective chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys. 20:1991;1183-1190.
10. Barcellos-Hoff M.H., Derynck R., Psang M.L.-S., Weatherbee J.A. Transforming growth factor beta activation in irradiated murine mammary gland. J Clin Invest. 93:1994;892-899.
11. Barcellos-Hoff MH. Redox mechanisms for activation of latent TGFβ. 43rd Annual Meeting of the Radiation Research Society, Abstract 1995;P14-196:153.
12. Boring C.C., Squires T.S., Tong T., Montgomery S. Cancer Statistics 1994. CA-A. Cancer J Clin. 44:1994;726.
13. Brattain M.G., Powell G., Sun L., Willson J.K.V. Growth factor balance in tumor progression. Curr Opin Oncol. 6:1994;77-81.
14. Brodsky R., Topolsky D., Crilley P., Bulova S., Brodsky I. Frequency of venoocclusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen. Am J Clin Oncol. 13:1990;221-225.
15. Broekelmann T.J., Limper A.H., Colby T.V., McDonald J.A. Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA. 88:1991;6642-6646.
16. Castilla A., Prieto J., Fausto N. Transforming growth factors beta-1 and alpha in chronic liver disease - effects of interferon alpha therapy. New Engl J Med. 324:1991;933-940.
17. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with >69.6 Gy in favorable patients with radiation therapy oncology group Stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
18. Cox J.D., Pajak T.F., Asbell S., Russell A.H., Pederson J., Byhardt R.W., Emami B., Roach M. Interruptions of high dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from three Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys. 27:1993;493-498.
19. Cromack D.T., Sporn M.B., Roberts A.B., Merino M.J., Dart L.L., Norton J.A. Transforming growth factor beta levels in rat wound chambers. J Surg Res. 42:1987;622-628.
20. Curtsinger L.J., Peitsch J.D., Brown G.L., von Fraunhofer A., Ackerman D., Polk H.C. Jr., Schultz G.S. Reversal of adriamycin impaired would healing by transforming growth factor beta. Surg Gynecol Obstet. 168:1989;517-522.
21. Dahms N.M., Lobel P., Kornfeld S. Mannose-6 phosphate receptors and lysosomal enzyme targeting. J Biol Chem. 264:1989;12115-12118.
22. Delvenne C.G., Winkler-Gol R.A., Piccart M.J., Hustin J., Michaux D., Leclercq G., Nogaret J.M., Autier P. Expression of c-erbB2, TGFβ-1 and pS2 genes in primary human breast cancers. Eur J Cancer. 28:1992;700-705.
23. Dennis P.A., Rifkin D.B. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose-6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA. 88:1991;580-584.
24. DeSouza A.T., Hankins G.R., Washington M.K., Fine R.L., Orton T.C., Jirtle R.L. Frequent loss of heterozygocity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene. 10:1995;1725-1729.
25. DeSouza A.T., Hankins G.R., Washington M.K., Orton T.C., Jirtle R.L. M6P/IGF2r gene is mutated in human hepatocellular carcinomas with LOH. Nat Genet. 11:1995;447-449.
26. Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C., Carey R.W., Frei E.F. III, Green M.R. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in Stage III NSCLC. New Engl J Med. 323:1990;940-945.
27. Dosoretz D.E., Galmarini D., Rubenstein J.H., Katin M.J., Blitzer P.H., Salenius S.A., Dosani R.A., Rashid M., Mestas G., Hannan S.E., Chadha T.T., Bhat S.B., Siegel A.D., Chandrahasa T., Metke M.P. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys. 27:1993;507-516.
28. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122.
29. Ettinger N.A., Truelock E.P. Pulmonary considerations of organ transplantation. Am Rev Respir Dis. 144:1991;213-223.
30. Fine A., Goldstein R.H. The effect of transforming growth factor beta on cell proliferation and collagen formation by lung fibroblast. J Biol Chem. 262:1987;3897-3902.
31. Finkelstein J.N., Johnston C.J., Baggs R., Rubin P. Early alterations in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys. 28:1994;621-631.
32. Fynan T.M., Reiss M. Resistance to inhibition of cell growth by transforming growth factor beta and its role in oncogenesis. Crit Rev Oncogenesis. 4:1993;493-540.
33. Ginsberg RJ, Kris NG, Armstrong, JG. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, 4th ed. Philadelphia, PA: JB Lippincott Co., 1993:673-722.
34. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax. 48:1993;959-966.
35. Gregor A., Macbeth F.R., Paul J., Cram L., Hansen H.H. Radical radiotherapy and chemotherapy in localized inoperable non-small cell lung cancer: a randomized trial. J Natl Cancer Inst. 85:1993;997-999.
36. Groen H.J.M., van Waarden M., Fokkema E., van der Leest A.H.D., Konings A.W.T., Vujaskovic Z. Plasma TGF-β levels during radiotherapy with or without carboplatin predicts pneumonitis in stage III non-small cell lung cancer (NSCLC). Proc 88th Ann Meet Am Assoc Cancer Res. 38:1997;330.
37. Hackman R.C., Madtes D.K., Petersen F.B., Clark J.G. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation. 47:1989;989-992.
38. Haffty B.G., Goldberg N.V., Gerstley J., Fischer D.B., Peschel R.E. Results of radical radiation therapy in clinical Stage I, technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 15:1988;69-73.
39. Hoyt B.G., Lazo J.S. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis. J Pharmacol Exp Ther. 246:1988;765-771.
40. Hoyt B.G., Lazo J.S. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J Pharmacol Exp Ther. 249:1989;38-43.
41. Ito N., Kawata S., Tamura S., Takaishi K., Shirai Y., Kiso S., Yabuuchi L., Matsuda Y., Nishioka M., Tarui S. Elevated levels of transforming growth factor beta mRNA and its polypeptide and human hepatocellular carcinoma. Cancer Res. 51:1991;4080-4083.
42. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGFβ-1 in patients with invasive prostate cancer. Nat Med. 1:1995;282-283.
43. Jirtle RL, Anscher MS, Alati T. Radiation sensitivity of the liver. In: Lett JT, Altman KI, editors. Advances in Radiation Biology 14. Relative Radiation Sensitivities of Human Organ Systems, Part II. San Diego, CA: Academic Press, 1990:269-312.
44. Johnston C.J., Piedboeuf B., Baggs R., Rubin P., Finkelstein J.N. Differences in correlation of mRNA gene expression in mice sensitive and resistant of radiation-induced pulmonary fibrosis. Radiat Res. 142:1995;197-203.
45. Kimchi A., Wang S.F., Weinberg R.A., Cheifetz S., Massague J. Absence of TGFβ receptors and growth inhibitory responses in retinoblastoma cells. Science. 240:1988;196-198.
46. Kong F.-M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., Jirtle R.L. Elevated plasma transforming growth factor β-1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 222:1995;155-162.
47. Kong FM, Anscher MS, Sporn T, Jirtle RL. Loss of mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) may lead to an elevated transforming growth factor β1 (TGFβ1) in circulation. In: Proceedings of the 45th Annual Meeting of the Radiation Research Society 1997:233.
48. Kong F.-M., Washington M.K., Jirtle R.L., Anscher M.S. Plasma transforming growth factor β-1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 16:1996;47-59.
49. Kong F-M, Anscher MS, Jirtle RL. Transforming growth factor beta. A plasma tumor marker. In: Hanausek M, editor. Methods in Molecular Biology: Tumor Marker Protocols. Totowa, NJ: Human Press, 1997;in press.
50. Krishnan E.C., Krishnan L., Jewell B., Bahatia P., Jewell W.R. Dose-dependent radiation effect on microvasculature and repair. J Natl Cancer Inst. 79:1987;1321-1325.
51. Kutcher G.J., Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 21:1991;137-146.
52. Lawrence T.S., Robertson J.N., Anscher M.S., Jirtle R.L., Ensminger W.D., Fajardo L.F. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1995;1237-1248.
53. Lawrence W.T., Norton J.A., Sporn M.B., Gorschboth C., Grotendorst G.R. The reversal of adriamycin-induced healing impairment with chemo attractants and growth factors. Ann Surg. 203:1985;142-147.
54. LeChevalier T., Arriagada R., Tarayre M., Lacombe-Terrier M.J., Laplanche A., Quoix E., Ruffie P., Martin M., Douillard J.Y. Significant effect of adjuvant chemotherapy on survival and locally advanced non-small cell lung cancer. J Natl Cancer Inst. 84:1992;58.
55. Letterio J.J., Geiser A.G., Kulkarni A.B., Roche N.S., Sporn M.B., Roberts A.B. Maternal rescue of transforming growth factor β-1 null mice. Science. 264:1994;1936-1938.
56. Lund L.R., Riccio A., Andreasen P.A., Neilsen P., Kristensen M., Laiho M., Saksela O., Blasi F., Dano K. TGFβ is a strong and fast-acting positive regulator of the level of Type 1 plasminogen activator inhibitor mRNA in WI-38 lung fibroblast. EMBO J. 6:1987;1281-1286.
57. Lyman J.T., Wolbarst A.V. Optimization of radiation therapy III. A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys. 113:1987;103-109.
58. Lyons R.M., Gentry L.E., Purchio A.F., Moses H.L. Mechanism of activation of latent recombinant transforming growth factor β-1 by plasmin. J Cell Biol. 110:1990;1361-1367.
59. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M., Willson J.K.V. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
60. Marks L.B., Spencer D.P., Bentel G.C., Sherouse G.W., Ray S., Sontag M., Coleman R.E., Jaszczak R.J., Turkington T.G., Tapson V., Prosnitz L.R. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys. 26:1993;659-668.
61. Mattson K., Holsti L.R., Holsti P., Jakobsson M., Kajanti M., Liippo K., Mantyla M., Niitamo-Korhonen S., Nikkanen V., Nordman E. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 24:1988;477-482.
62. McDonald G.B., Schulman H.M., Wolford J.L., Spencer G.D. Liver disease after human marrow transplantation. Semin Liver Dis. 7:1987;210-229.
63. Morton R.F., Jett J.R., McGinnis W.L., Earle J.D., Therneau T.M., Krook J.E., Elliott T.E., Mailliard J.A., Nelimark R.A., Maksymiuk A.W., Drummond R.G., Laurie J.A., Kugler J.W., Anderson R.T. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med. 115:1991;681-686.
64. Murase T., Anscher M.S., Petros W.P., Peters W.P., Jirtle R.L. Changes in plasma transforming growth factor beta in response to high dose chemotherapy for Stage II breast cancer: possible implications for the prevention of hepatic venoocclusive disease in pulmonary drug toxicity. Bone Marrow Transplant. 15:1995;173-178.
65. Mustoe T.A., Pierce G.F., Thomason A., Gramates P., Sporn M.B., Deuel T.F. Accelerated healing of incisional wounds in rats induced by transforming growth factor beta. Science. 235:1987;1333-1336.
66. Newman M.J. Transforming growth factor β and the cell surface in tumor progression. Cancer Metastasis Rev. 12:1993;239-254.
67. Noble P.W. The pulmonary complications of bone marrow transplantation in adults. West J Med. 150:1989;443-449.
68. Norgaard P., Damstrup L., Rygaard K., Spang-Thomsen M., Skovgaard Poulsen H. Growth suppression by transforming growth factor β1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer. 69:1994;802-808.
69. O'Connor-McCourt M.D., Wakefield L.M. Latent transforming growth factor beta in serum: a specific complex with alpha-2 microglobulin. J Biol Chem. 262:1987;14090-14099.
70. Perez C.A., Bauer M., Edelstein S., Gillespie B.W., Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Rad Oncol Biol Phys. 12:1986;539-547.
71. Perez C.A., Stanley K., Rubin P., Kramer S., Brady L.W., Marks J.E., Perez-Tamayo R., Brown G.S., Concannon J.P., Rotman M. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung. Cancer. 45:1980;2744-2753.
72. Postlewaite A.E., Keski-Oja J., Moses H.L., Kang A.H. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med. 165:1987;251-256.
73. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Liotta L.A., Falanga V., Kehil J.H., Fauci A.S. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 83:1986;4167-4171.
74. Rubin P., Finkelstein J.N., Shapiro D. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys. 24:1992;93-101.
75. Rubin P., Johnston C.J., Williams J.P., McDonald S., Finkelstein J.N. A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:1995;99-109.
76. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A.B., Sporn M.B., Thorgeirsson S.S. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 92:1995;2572-2576.
77. Saunders M.I., Barltrop M.A., Rassa P., Anderson P.J., Dische S. The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys. 10:1984;503-508.
78. Saunders M.I., Dische S., Grosch E.J., Fermont D.C., Ashford R.F.U., Maher E.J., Makepeace A.P. Experience with CHART. Int J Radiat Oncol Biol Phys. 21:1991;871-878.
79. Saunders M.I., Dische S. Randomized multicenter trial of CHART versus conventional radiotherapy in non-small cell lung cancer - interim results and implications. Int J Radiat Oncol Biol Phys. 36:1996;208.
80. Schaake-Koning C., VanDenBogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., Kirkpatrick A., Koolen M., Maat B., Nijs A., Renaud A., Rodrigus P., Schuster-Uitterhoeve L., Sculier J.-P., van Zandwijk N., Bartelink H. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. New Engl J Med. 326:1992;524-530.
81. Shirai Y., Kawata S., Tamura S., Ito N., Tsushima H., Takaishi K., Kiso S., Matsuzawa Y. Plasma transforming growth factor β-1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer. 73:1994;2275-2279.
82. Shulman H.M., Gown A.M., Nugent B.J. Hepatic venoocclusive disease after bone marrow transplantation: immunohistochemical identification of the material with an occluded central venules. Am J Pathol. 127:1987;549-558.
83. Sporn M.B., Roberts A.B., Shull J.H., Smith J.M., Ward J.M. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science. 219:1983;1329-1331.
84. Steele GG. Growth Kinetics of Tumors. Oxford: Clarendon Press, 1977.
85. Stuschke M., Thames H.D. Hyperfractionated radiotherapy of human tumors: overview of randomized clinical trials. Int J Radiat Oncol Biol Phys. 37:1997;259-267.
86. Sue S.R., Chari R.S., Kong F.-M., Mills J.J., Fine R.L., Jirtle R.L., Meyers W.C. Transforming growth factor beta receptors and mannose-6-phosphate/insulin-like growth factor II receptor expression in human hepatocellular carcinomas. Ann Surg. 222:1995;171-178.
87. Tucker S.L., Geara F.B., Peters L.J., Brock W.A. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal tissue radiosensitivity? Radiother Oncol. 38:1996;103-114.
88. Wright J.A., Turley E.A., Greenberg A.H. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy. Crit Rev Oncogenesis. 4:1993;473-492.
89. Zugmaier G., Paik S., Wilding G., Knabbe C., Bano M., Lupu R., Deschauer B., Simpson S., Dickson R.B., Lippman M. Transforming growth factor β1 induces cachexia and systemic fibrosis without antitumor effect in nude mice. Cancer Res. 51:1991;3590-3594.